TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04380103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOXIRI/Bevacizumab
Description: bevacizumab 5mg/kg on day1, irinotecan 150mg/m2 or 165mg/m2 on day1, oxaliplatin 85mg/m2 on day1 and capecitabine 1000mg/m2 twice a day on day1-7 repeated every 2 week for 12 cycles, after 12 cycles, bevacizumab 5mg/kg on day 1 and capecitabine 1000mg/m2 twice a day on day1-7 as maintenance therapy repeated every 2 week
Study: NCT02425605

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CCRT
Description: The subject is treated with a total of 45 Gy of external beam radiotherapy (1.8 Gy per session, 5 sessions a week, for 5 weeks), with hepatic arterial infusion of 5-flourouracil (5-FU) during the first and last 5 days of radiation therapy (5-FU 500 mg infusion for 5 hours) for radiosensitization through the pre-inserted chemoport.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Four weeks after completion of CCRT, the subject is given daily sorafenib treatment and will be followed for survival.
Study: NCT03254927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-3379 and cetuximab
Description: Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.
Study: NCT01584687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: The patients will receive Omalizumab according to their age and weight for 4 months.
Study: NCT03313752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10Mg Tab
Description: Dapagliflozin, will be administered according to the approved posology and to the approved dose as stated by Local Health Indication and by the Drug Brochure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00062842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study: NCT01899729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-8400 Regimen 1
Description: IMO-8400 0.075 mg/kg q wk x 12 wk by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-8400 Regimen 2
Description: IMO-8400 0.15 mg/kg q wk x 12 wk by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-8400 Regimen 3
Description: IMO-8400 0.3 mg/kg q wk x 12 wk by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Saline q wk x 12 wk by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMO-8400 Regimen 4
Description: IMO-8400 0.6 mg/kg q wk x 12 wk by subcutaneous injection
Study: NCT01808040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK700
Description: dose is dependant on dose escalation timepoint and dose expansion cohort dose will be the RP2D determined based on the dose escalation cohort final dose recommendation
Study: NCT03706144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prodigy Math Training
Description: https://www.prodigygame.com/
Study: NCT01910142

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin K
Description: A calcium product will be given either with or without vitamin K. Each intervention will last for 5 weeks, each followed by a 5 week wash-out. The first intervention will start about 4 months after inclusion and the single 41Ca bolus.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: calcium
Study: NCT02445352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R207 5/10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 10mg
Study: NCT02168179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dermatologic complications management/prevention
Description: Apply KeraStat Skin Therapy topically
Study: NCT02311621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)
Description: Intravenous infusion of autologous T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt (2nd generation T cells)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells)
Description: Intravenous infusion of autologous T cells transduced to express CD28:4-1BB:zeta CD171CAR and EGFRt

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells)
Description: Intravenous infusion of autologous T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt (long spacer 2nd generation T cells)
Study: NCT02445352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R207 10/10mg
Study: NCT01360463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Drug and Risk Counseling (BDRC)
Description: The BDRC counseling is rooted in cognitive behavioral theory. During one hour sessions, the counselors help participant identify short term behavioral goals and work with the participant to develop strategies to achieve their goals. These plans are referred to as contracts and these contracts are reviewed and revised at each subsequent session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: methadone maintenance treatment
Description: daily individualized doses of methadone will be provided by the program staff.
Study: NCT01987310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: atorvastatin 20 mg per day for 6 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle counseling
Description: lifestyle modification by dietician counseling and follow up
Study: NCT03988686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy plus standard care
Description: To add radical prostatectomy on the basis of current standard of care for those with oligometastatic prostate cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care for metastatic prostate cancer
Description: androgen deprivation therapy with or without other systemic therapies based on current guidelines for metastatic prostate cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care for metastatic prostate cancer
Description: androgen deprivation therapy with or without other systemic therapies based on current guidelines for metastatic prostate cancer
Study: NCT02794870

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV LID ΔM2-2 1030s vaccine
Description: 10\^5.0 PFU; administered as nose drops

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic diluent, administered as nose drops
Study: NCT03062046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF ablation
Description: RF ablation
Study: NCT00782405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: XR, 150-300mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirtazapine
Description: 30-45 mg
Study: NCT01888510

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo conventional free breathing CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4-dimensional computed tomography
Description: Undergo 4D CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo ABC CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cone-beam computed tomography
Description: Undergo ABC CBCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cone-beam computed tomography
Description: Undergo free breathing CBCT
Study: NCT04194294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Before induction of anesthesia; children in group LID received an iv bolus dose of LIDOCAINE 1 mg/kg over 5 minutes followed by 1 mg Kg-1 h-1 ivi until the start of skin closure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Na CL 0.9%
Description: Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of LIDOCAINE.
Study: NCT00555841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALC and Placebo
Description: ALC and Placebo
Study: NCT02168179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT00555841

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALC and Placebo
Description: ALC and Placebo
Study: NCT04590040

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0% nano-HAP toothpaste

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 15% nano-HAP toothpaste
Description: Toothpaste with identical base formulation as the placebo containing 15% nano-HAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5% KNO3 toothpaste
Description: Toothpaste with identical base formulation as the placebo containing 5% KNO3
Study: NCT02965586

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intrathecal
Description: intrathecal block will be performed in sitting position using 25 G spinal needle at either the L3-L4 or L4-L5 intervertebral spaces.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal
Description: intrathecal block will be performed in sitting position using 25 G spinal needle at either the L3-L4 or L4-L5 intervertebral spaces.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal
Description: intrathecal block will be performed in sitting position using 25 G spinal needle at either the L3-L4 or L4-L5 intervertebral spaces.
Study: NCT01577589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 mg ceftaroline fosamil in 50 ml infusion volume
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in 50 ml infusion volume
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 ceftaroline fosamil in 250 ml infusion volume
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in 250 ml infusion volume
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 mg ceftaroline in 100 ml infusion volume
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in 100 ml infusion volume
Description: IV infusion
Study: NCT02445352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Study: NCT01540994

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Stereotactic Body Radiation Therapy
Study: NCT02445352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R207 20/10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)
Study: NCT03803982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Neuromuscular Blockade
Description: The proposed intervention in this study is delivery of an anesthetic with Deep Neuromuscular Blockage (NMB), which will be defined as a TOF of 0 and 2-3 twitches in the post-tetanic count.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex will be used to reverse the deep neuromuscular blockade in the experimental group.
Study: NCT03494101

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples will be collected and analyzed at different study time points

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples will be collected and analyzed at different study time points

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples will be collected and analyzed at different study time points

Intervention type: OTHER
Intervention: Stool samples
Description: Stool samples will be collected and analyzed at different study time points

Intervention type: OTHER
Intervention: Stool samples
Description: Stool samples will be collected and analyzed at different study time points

Intervention type: OTHER
Intervention: Stool samples
Description: Stool samples will be collected and analyzed at different study time points

Intervention type: OTHER
Intervention: Clinical information
Description: Clinical information will be collected at different study time points using questionnaires

Intervention type: OTHER
Intervention: Clinical information
Description: Clinical information will be collected at different study time points using questionnaires

Intervention type: OTHER
Intervention: Clinical information
Description: Clinical information will be collected at different study time points using questionnaires
Study: NCT03328975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: The overall purpose of this study is to evaluate the effect of a corticosteroid shoulder injection on glucose levels in insulin-dependent diabetic men and women.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the placebo group will not receive the corticosteroid medication in their injection to treat the inflammation and pain in their shoulder. Instead, they will receive an injection of 5 mL lidocaine only.
Study: NCT02988635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Palliative Care
Description: Subjects who are randomized to the Standard Oncology Care with Early Palliative Care will meet with the palliative care team at their next medical oncology or infusion visit. They will meet with the palliative care clinician at least every three weeks. They will complete questionnaire at 12 weeks after enrollment.
Study: NCT01761760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Videogame-based smoking cessation intervention
Description: Patients will enroll in a videogame that is intended to help them quit smoking. They will be given goals for quitting (based on carbon monoxide readings submitted over a secure internet server) and will earn game-based incentives either contingent or noncontingent on meeting those goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Videogame-based smoking cessation intervention
Description: Patients will enroll in a videogame that is intended to help them quit smoking. They will be given goals for quitting (based on carbon monoxide readings submitted over a secure internet server) and will earn game-based incentives either contingent or noncontingent on meeting those goals.
Study: NCT02021513

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Fish Oil (2.25gm EPA and 2.25gm DHA total)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: Placebo group
Study: NCT02882308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 50/25 mg BD split x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60 mg/m\^2 d1-d5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg BD x 21-28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg BD x 21-28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg d1
Study: NCT04660240

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abluminus Sirolimus Eluting Stent System (ASES)
Description: The procedure will be conducted in accordance with the CE mark instructions for use for the ASES.~The need or not for postdilation in any segment of the stent will be at the discretion of the operator, seeking its adequate expansion and apposition. To consider PCI to be successful, residual stenosis must be less than or equal to 30% by angiography at the end of the procedure, including the absence of coronary dissection that compromises distal flow or a hemodynamically significant pressure gradient across the lesion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orsiro Sirolimus Eluting Coronary Stent System (OSES)
Description: The procedure will be conducted in accordance with the CE mark instructions for use for the OSES.~The need or not for postdilation in any segment of the stent will be at the discretion of the operator, seeking its adequate expansion and apposition. To consider PCI to be successful, residual stenosis must be less than or equal to 30% by angiography at the end of the procedure, including the absence of coronary dissection that compromises distal flow or a hemodynamically significant pressure gradient across the lesion.
Study: NCT00909389

Intervention type: DRUG
Intervention: Vytorin (R) (Ezetimibe + Simvastatin)
Description: Vytorin (R) (Ezetimibe + Simvastatin) 1 tablet once daily to be taken by mouth in the evening for 28 days
Study: NCT01542151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time of labor induction
Description: Assigned time of labor induction - morning or evening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time of labor induction
Description: Assigned time of labor induction - morning or evening
Study: NCT00270907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-2103
Description: 135 mg/m\^2 IV on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 IV on Day 1 and 8.
Study: NCT03645707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAR Training and Psychoeducational Sessions
Description: Participation in the CAR Training Program, a 1-day training program developed by the J\&J Human Performance Institute (HPI). The CAR Training Program uses a holistic approach that focuses on moving between stress and strategic recovery to help build resilience and enable higher performance.~Participants will attend eight weekly follow-up psychoeducational group sessions facilitated by a licensed mental health counselor that will meet for 90 minutes. The themes of these sessions will be RISE - Resilience, Insight, Self-Compassion, and Empowerment. Due to limited time and flexibility in sessions, participants will practice skills through optional homework activities to facilitate learning between sessions.
Study: NCT02040441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Standard care
Description: Standard diabetes care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Standard diabetes care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard diabetes care
Study: NCT03155516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Good pain management (GPM) procedure
Description: In the GPM ward, a close pain assessment will be carried within 1 hour after admission. After the assessment, patient will be given analgesic treatment as needed, by acceptable route, frequency and dosage. A good titration is required in GPM ward. Patient will be close monitor his/her pain level regarding pain score. In opioid use, when patient complains patient level ≥ 4, low dose strong opioids will be introduced in patient suffering with moderate pain.~Compare with current practice, GPM ward will perform pain assessment with higher frequency for adjusting of analgesic medications if required.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current practice procedure
Description: Current practice clinical procedure for pain management
Study: NCT01860352

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fish OIl
Study: NCT02180737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmeditomedine
Study: NCT02645331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remind-to-move

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified constraint induced movement therapy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Conventional rehabilitation
Study: NCT06321679

Intervention type: PROCEDURE
Intervention: Imaging evaluation
Description: each patient will undergo imaging with CT, BS and WB-MRI at each study timepoint
Study: NCT02208739

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy
Description: All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nonsurgical periodontal therapy
Description: All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral hygiene instructions
Description: All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.
Study: NCT00598572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine Mesylate
Description: Various dose-regimens ranging from 7 mg/kg to 125 mg/kg (with a maximum allowable total daily dose of 6000 mg at any of the tested dose tiers, regardless of patient's weight), administered daily by IV infusion for three consecutive days.
Study: NCT02184689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexinidazole
Study: NCT02445352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)